Stockscreener 앱 받기
1.37
9.27%
-0.14
시간 외 거래:
1.40
0.03
+2.19%
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Editas Medicine Reports Progress in Gene Editing - TipRanks
Gene Editing Market Future Business Opportunities 2025-2032 | - openPR
Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely - Yahoo Finance
Editas Medicine’s SWOT analysis: gene editing firm pivots strategy amid stock volatility - Investing.com
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Analysts - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Editas Medicine Inc.’s Stock Volatility: Key Risks and Investor Considerations - TipRanks
Editas Medicine at Leerink’s Global Healthcare Conference: In Vivo Focus By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Issues Earnings Results - MarketBeat
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential - MSN
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN
Editas Medicine (NASDAQ:EDIT) Posts Quarterly Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Sell Rating for Editas Medicine Amid Strategic Shift and Competitive Pressures - TipRanks
Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position - TipRanks
Editas Medicine, Inc. to Host Earnings Call - ACCESS Newswire
Editas Medicine (EDIT) Stock Price, News & Analysis - MarketBeat
Global Genome Editing Market to Grow Rapidly at a CAGR ~13% by 2032 | DelveInsight - GlobeNewswire Inc.
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates - MSN
Editas: Q4 Earnings Snapshot - Midland Daily News
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates - GlobeNewswire
Editas Medicine Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EDITAS MEDICINE Earnings Results: $EDIT Reports Quarterly Earnings - Nasdaq
Editas Medicine Inc Reports Q4 2024 Loss of $0.55 EPS and $30.6 Million Revenue, Missing Estimates - GuruFocus.com
Editas Medicine shares fall as Q4 earnings miss estimates - Investing.com
EDITAS MEDICINE, INC. Q4 Loss Increases, Misses Estimates - Nasdaq
Editas Medicine reports Q4 EPS (55c), consensus (33c) - TipRanks
Can Editas Medicine's Strategic Shift to In Vivo Editing Reverse Its $237M Annual Loss? - StockTitan
Editas Medicine Q4 2024 Earnings Preview - MSN
Editas Medicine Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Top 5 CRISPR Companies To Invest In (March 2025) - Securities.io
Reviewing Aligos Therapeutics (NASDAQ:ALGS) & Editas Medicine (NASDAQ:EDIT) - Defense World
Editas Medicine Q1 2024 Earnings Preview - MSN
Editas Medicine (EDIT) Projected to Post Earnings on Wednesday - MarketBeat
Editas: The high-risk, high-reward gene editing pioneer - BioCentury
Peering Into Editas Medicine's Recent Short Interest - Benzinga
Editas Medicine to Announce Fourth Quarter/Full Year 2024 - GlobeNewswire
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March - The Manila Times
Editas Medicine to Announce Q4 2024 Financial Results and Upcoming Investor Conference Participation - Nasdaq
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate - The Bakersfield Californian
Access Editas Medicine's Full March Lineup: Earnings Plus 3 Major Healthcare Conferences - StockTitan
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $7.00 Average PT from Analysts - MarketBeat
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 200-Day Moving AverageShould You Sell? - MarketBeat
1.39%
0.55%
자본화:
|
볼륨(24시간):